![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Validation of a Modified Pediatric Formulation of Sofosbuvir and Daclatasvir in Genotype-4 HCV-infected Children Weighing 17-35 Kg
|
|
|
EASL 2024 June 5-8
Ahmed Farrag 1, Maggie Abbassi 1, Fatma Ebeid 2, Tim Cressey 3, Philippa Easterbrook 4, Nirmeen Sabry 5, Manal El-Sayed 6
![0618241](../images/061824/061824-25/0618241.gif)
![0618242](../images/061824/061824-25/0618242.gif)
![0618243](../images/061824/061824-25/0618243.gif)
![0618244](../images/061824/061824-25/0618244.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|